Copper Peptides for Skin vs. Scalp: Same Ingredient, Different Job

"Copper peptides" gets marketed as if it were a single ingredient with a single story, but the skincare claim and the hair-growth claim actually rest on two different tripeptides. GHK-Cu is the one with a real, if still preliminary, case for facial skin: solid cell and tissue-model evidence for supporting collagen, with a thin layer of human trial data sitting on top of it. AHK-Cu is the one behind the hair-growth marketing, and its entire case is a single 2007 laboratory study on isolated hair follicles, not a clinical trial on anyone's actual scalp. A serum that combines both peptides in one bottle for use on the face and the scalp isn't claiming that one ingredient does everything. It's applying a skin-support ingredient to two areas of skin, which is a considerably more modest claim than "copper peptides regrow hair."

• GHK-Cu (the facial-skin peptide) and AHK-Cu (the hair-and-scalp peptide) are different molecules with separate, non-interchangeable evidence bases.
• GHK-Cu's strongest support comes from fibroblast and ex-vivo skin models; the human clinical data is sparse, and a 2026 systematic review found only two relevant facial studies.
• AHK-Cu's hair claim rests on one 2007 study carried out on isolated follicles and cultured cells outside the body, not on a living scalp.
• Neither peptide is comparable to minoxidil, the only ingredient in a hair-loss routine with strong, approved regrowth evidence behind it.
• Used on both the face and the scalp, this kind of serum is best understood as a skin-condition product that supports the skin around a treatment, not a hair-growth treatment itself.

GHK-Cu and AHK-Cu: two different copper peptides, two different stories

Copper peptide is a category name, not a specific ingredient, and that distinction matters more than it looks. The skincare claim is built on GHK-Cu, a tripeptide that occurs naturally in human plasma, saliva and urine, at levels that decline as people age (source: GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration). That natural decline is the biological detail that first drew research interest: if a substance the body already makes falls off with age, replacing it topically looked like a reasonable hypothesis to test.

The hair-growth claim is built on a different, shorter tripeptide, AHK-Cu, tested in a separate line of research with its own separate limits. The two peptides share a copper-binding structure and a marketing category, and not much else. Treating a study of one as evidence for the other is the error to watch for when a product page or a shopping listing talks about "copper peptides" as though the word covers a single, unified body of proof. For a broader look at how peptides work as an ingredient class and where GHK-Cu sits among them, see this explainer on peptides in skincare; this article's job is narrower, comparing what each specific copper peptide has actually been shown to do.

What the skin evidence for GHK-Cu actually shows

In fibroblast cultures and ex-vivo skin models, GHK-Cu is associated with increased synthesis of collagen and other matrix proteins, which is the mechanism the skincare claim rests on (source: GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration). A 2023 study combining GHK-Cu with hyaluronic acid at an optimised ratio reported a substantial rise in collagen IV synthesis in a cell model and a smaller but still measurable rise in an ex-vivo human skin model (source: Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation). Those are genuine, reproducible results, and they explain why the ingredient keeps turning up in serums aimed at firmness and fine lines.

The honest caveat is what happens once the question moves from tissue in a dish to skin on a real face. A 2026 systematic review that went looking specifically for human cosmetic trials of GHK-Cu found only two: a 13-person study after CO2 laser treatment that came back negative on its objective measurements, and a positive 18-person split-face study on eyebrow hair growth that never defined the GHK-Cu formulation used or how much of it actually reached the skin. That second study is worth pausing on, because it measured a hair outcome rather than a skin-firmness or collagen outcome, so it doesn't really belong in a tally of facial-skin trials even though it's the more encouraging of the two results. It also means GHK-Cu has one small, loosely described piece of human evidence pointing toward hair growth, sitting alongside a laboratory case for AHK-Cu that has never had a living scalp behind it at all. That doesn't overturn the distinction this article is drawing between the two peptides, since the study's exposure conditions are too vague to lean on, but it's a genuine complication worth naming rather than quietly filing under "skin evidence." The review's own conclusion was that clinical evidence for GHK-Cu "remains sparse and does not meet contemporary active-entity quality standards" (source: GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo). That's a plausible, mechanistically interesting ingredient with a couple of small, imperfect human studies behind it, not a proven one, and the difference is worth holding onto rather than rounding up to "clinically proven."

What "ex-vivo" and "fibroblast model" actually mean for a reader

A fibroblast model means the researchers grew skin cells in a dish and measured how those cells responded to the peptide, which tells you something real about a cellular mechanism but nothing about how the compound behaves once it has to cross intact skin and reach those cells in a living person. An ex-vivo skin model is a step closer: a section of real skin tissue, kept alive outside the body for the length of the experiment, tested with the compound applied the way it would be in use. Both are useful early-stage evidence, and both stop short of the question a reader actually wants answered, which is what happens on a face over twelve weeks of normal use. That question is what a genuine human clinical trial answers, and GHK-Cu currently has very few of them.

Where the hair-growth story for copper peptides comes from

The hair claim traces back to a single 2007 study that applied AHK-Cu to isolated human hair follicles kept alive in organ culture, and separately to cultured dermal papilla cells, the cells at the base of a follicle that help drive hair growth. At the concentrations tested, the follicles elongated more and the dermal papilla cells proliferated more than in untreated controls, and at the highest concentration tested, fewer of those cells died (source: The effect of tripeptide-copper complex on human hair growth in vitro). That is a real result, and it is also, by its own design, a result recorded in a dish and in follicles removed from the body, not in a living scalp with blood supply, hormones and everything else that changes once tissue stays attached to a person.

One programme did go further than the lab bench: a copper peptide scalp solution reached company-run human trials for pattern hair loss in the 1990s. It never reached regulatory approval, and the full results were never published anywhere a reader can independently check them, so there is nothing verifiable to cite from that programme beyond the fact that it happened and didn't lead anywhere. Between the 2007 organ-culture study and that unpublished trial, there is no controlled human trial showing that a copper peptide grows hair on an intact scalp. None of this is comparable to minoxidil, the only ingredient in a hair-loss routine with strong, approved regrowth evidence behind it, and minoxidil's own approval is specific rather than universal: it has no effect on a receding hairline and works best in people under 40 with recent hair loss at the crown (source: Minoxidil Topical, MedlinePlus Drug Information). Grading AHK-Cu honestly means placing it well below that bar, not implying it belongs in the same conversation.

So why put a copper peptide serum in a hair-loss product range at all?

The scalp is skin, and most of a typical hair-loss routine is hard on it. A minoxidil solution is carried in alcohol with propylene glycol, and a dermaroller deliberately opens the surface to do its job. A serum aimed at the condition of the skin itself, rather than at the hair cycle, has a reasonable place alongside those treatments precisely because they're the ones putting the skin under strain in the first place. That's a different role from claiming the serum grows hair, and the distinction is the whole point of grading GHK-Cu and AHK-Cu separately rather than borrowing confidence from whichever peptide sounds more convincing.

That also settles what looks like a choice but isn't really one. Comparing this serum against starting Minoxidil Topical Solution USP, 5% isn't a fair comparison, because they're not doing the same job: one has approved regrowth evidence behind it, and the other supports the skin that treatment sits on. The honest sequence is treatment first, and a copper peptide serum alongside it if the skin needs the support, not one instead of the other.

Using one serum on both the face and the scalp

A serum built for dual use still needs applying with the two areas' different goals in mind, since a scalp and a face aren't asking for the same thing from the same bottle. On the scalp, part the hair into rows and place a few drops along each parting across the area being treated, working roughly half a pipette across the whole scalp; on the face, three or four drops is enough to cover the whole area including the hairline. Both applications go on clean, properly dry skin at night, because damp skin dilutes the serum and spreads it unevenly rather than where it was placed.

Two sequencing details are worth knowing before adding this into an existing routine. Copper complexes are destabilised by strong acids and by direct vitamin C, so keep exfoliating acids and vitamin C for the morning and this serum for the night rather than layering them in the same sitting; anyone already managing that kind of routine around a retinol or an acid wash may find this guide to moisturising reactive, treatment-irritated skin useful for the wider sequencing question. And on a scalp that also gets minoxidil in the evening, apply the copper peptide serum first and let it absorb fully before the minoxidil goes on, since minoxidil's own label advises against layering other products on the scalp at the same time. For the fuller picture of what can and can't safely go on a minoxidil-treated scalp, this article on moisturising alongside minoxidil covers the sequencing in more depth than fits here.

Put together, the honest version of this ingredient story is less dramatic than the marketing around "copper peptides" usually suggests, and more useful for it. GHK-Cu has a real, still-thin case for supporting facial skin. AHK-Cu has a lab result on isolated follicles and nothing published from a living scalp. A serum that uses both, on both areas, for skin support rather than hair regrowth, is a fair description of what it actually does. Anyone weighing it against the wider range can browse the rest of the Skin Care hub for related ingredient breakdowns before deciding what, if anything, to add.